Product logins

Find logins to all Clarivate products below.


  • The document complements our standalone (detailed) company profile (which emphasis on clinical aspects more) by adding the business facet covering overall strategy, Geographical focus, Therapy area evolution within the portfolio, SWOT analysis- and how the company’s business has evolved in the last couple of years.
  • The document gives a bird eyes view about the expected sales performance of the company covering the top-performing brands and therapy area focus based on their adopted business strategy. And how the company is fairing compared to its peers and what ranking changes are expected by the end of the forecast period.

Related Market Assessment Reports

Report
Fragile X Syndrome – Executive Insights – Fragile X Syndrome | Executive Insights | US/EU5/China
Report
Malignant Melanoma | Disease Landscape & Forecast | G7 | 2021
The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK …
Report
Psoriasis | Disease Landscape and Forecast | G7 | 2021
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
Report
Hemophilia | Disease Landscape and Forecast | Hemophilia A | G7 | 2021
DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…
Report
Endometrial Carcinoma | Disease Landscape & Forecast | G7 | 2021
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…